Last $147.98 USD
Change Today -1.24 / -0.83%
Volume 829.1K
As of 8:04 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BCR) Key Developments

C. R. Bard, Inc. Announces the U.S. Food and Drug Administration Approval of the Lutonix 035 Drug Coated Balloon Catheter for Percutaneous Transluminal Angioplasty

C. R. Bard Inc. announced the U.S. Food and Drug Administration approval of the Lutonix 035 Drug Coated Balloon Catheter for percutaneous transluminal angioplasty, after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in June 2014. The Lutonix 035 DCB--the first and only FDA-approved DCB in the U.S.-- is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries. FDA approval of the Lutonix 035 DCB was supported by results of the LEVANT 2 pivotal study, a global, prospective, single-blind, randomized, 54-site study (42 sites in the U.S. and 12 in Europe) that enrolled all patients under one protocol. At one year, the LEVANT 2 study demonstrated improved patency of the Lutonix 035 DCB compared to standard PTA: 73.5% vs. 56.8%, p<0.001 by Kaplan-Meier time-to-event analysis. It also demonstrated clinical benefits of sustained improvement in Rutherford Class and improved walking distance scores. The LEVANT 2 study followed a rigorous blinding protocol designed to reduce bias in the results to accurately and scientifically assess and compare the long-term performance of key clinical measures. The LEVANT clinical program, which includes registry data, enrolled more than 1,000 patients and demonstrated robust safety of the device comparable to PTA, including the same low rate of distal embolic events and rate of reintervention for thrombotic events.

C. R. Bard, Inc. Declares Quarterly Dividend, Payable on October 31, 2014

The board of directors of C. R. Bard Inc. declared a regular quarterly dividend of 22 cents per share on its common stock. The current indicated annual dividend rate is 88 cents per share. The dividend is payable on October 31, 2014 to shareholders of record at the close of business on October 20, 2014.

CR Bard Inc. to Report Q3, 2014 Results on Oct 22, 2014

CR Bard Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Daylight on Oct 22, 2014

CR Bard Inc., Q3 2014 Earnings Call, Oct 22, 2014

CR Bard Inc., Q3 2014 Earnings Call, Oct 22, 2014

3M Co, CareFusion Corp and C.R. Bard Eyes ConvaTec From Avista Capital Partners And Nordic Capital

3M Company (NYSE:MMM), CareFusion Corporation (NYSE:CFN) and C.R. Bard Inc. (NYSE:BCR) seeks to acquires ConvaTec Inc. from its private equity owners including Avista Capital Holdings, L.P and Nordic Capital, Reuters reported citing people familiar with the matter. The deal is believed to be explored by 2015. ConvaTec Inc. would review any compelling offer that would come before 2015. ConvaTec Inc., Avista Capital Holdings, L.P, Nordic Capital, 3M Company, CareFusion Corporation and C.R. Bard Inc could not be reached for comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCR:US $147.98 USD -1.24

BCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $56.69 USD +0.02
Edwards Lifesciences Corp $105.26 USD -0.55
Endo International PLC $63.19 USD -0.54
Varian Medical Systems Inc $80.99 USD -0.85
View Industry Companies
 

Industry Analysis

BCR

Industry Average

Valuation BCR Industry Range
Price/Earnings 15.2x
Price/Sales 3.6x
Price/Book 6.6x
Price/Cash Flow 14.1x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.